Temozolomide, when given in primary glioblastoma multiforme (GBM) in both concomitant and adjuvant phases may prolong survival and delay progression compared to radiotherapy alone. In recurrent GBM, temozolomide may improve time to progression but does not improve overall survival, when compared with standard chemotherapy Temozolomide for High Grade Glioma.